← Back to Clinical Trials
Recruiting NCT05277272

NCT05277272 INTO-HLH: A Disease Registry for Patients With Hemophagocytic Lymphohistiocytosis (HLH)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05277272
Status Recruiting
Phase
Sponsor Children's Hospital Medical Center, Cincinnati
Condition Hemophagocytic Lymphohistiocytoses
Study Type OBSERVATIONAL
Enrollment 200 participants
Start Date 2021-12-31
Primary Completion 2027-01

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 200 participants in total. It began in 2021-12-31 with a primary completion date of 2027-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this observational study is to collect data on the natural history of disease of patients with Hemophagocytic Lymphohistiocytosis (HLH) including diagnosis, treatments, responses, and outcomes.

Eligibility Criteria

Inclusion Criteria: * Patients with clinically suspected or confirmed HLH, including those meeting the HLH-2004 diagnostic criteria (primary or secondary forms, including malignancy) and other forms of HLH (macrophage activation syndrome \[MAS\], cytokine release syndrome \[CRS\], etc.) * Signed and dated informed consent and assent (adolescents) Exclusion Criteria: * None

Contact & Investigator

Central Contact

Michael Jordan, MD

✉ Michael.Jordan@cchmc.org

📞 (513) 803-9063

Principal Investigator

Michael Jordan, MD

STUDY CHAIR

Children's Hospital Medical Center, Cincinnati

Frequently Asked Questions

Who can join the NCT05277272 clinical trial?

This trial is open to participants of all sexes, studying Hemophagocytic Lymphohistiocytoses. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05277272 currently recruiting?

Yes, NCT05277272 is actively recruiting participants. Contact the research team at Michael.Jordan@cchmc.org for enrollment information.

Where is the NCT05277272 trial being conducted?

This trial is being conducted at Cincinnati, United States.

Who is sponsoring the NCT05277272 clinical trial?

NCT05277272 is sponsored by Children's Hospital Medical Center, Cincinnati. The principal investigator is Michael Jordan, MD at Children's Hospital Medical Center, Cincinnati. The trial plans to enroll 200 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology